Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSYN 10%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLINIMIX E 2.75/5 is a combination of amino acids, electrolytes, and dextrose used for parenteral nutrition. The amino acids provide substrates for protein synthesis, dextrose supplies caloric energy, and electrolytes maintain acid-base and fluid balance. Calcium is included for bone health and neuromuscular function.
Aminosyn 10% provides a mixture of essential and non-essential amino acids to support protein synthesis and maintain nitrogen balance in patients unable to tolerate adequate oral or enteral nutrition. Each amino acid serves as a substrate for protein synthesis, hormone production, and other metabolic processes.
Parenteral nutrition for patients with or without electrolyte abnormalities who require intravenous feeding,Peripheral or central venous nutrition for prevention or treatment of negative nitrogen balance
Parenteral nutrition for patients with inadequate oral or enteral intake,Prevention of nitrogen loss in catabolic states,Treatment of negative nitrogen balance
Intravenous administration. The dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 1 to 2 L per day of CLINIMIX E 2.75/5 with electrolytes in 5% dextrose with calcium, infused at a rate not exceeding 4 mg/kg/min of dextrose (or as tolerated).
Intravenous infusion: 1-1.5 g/kg/day (as amino acids), typically 500 m L of 10% solution (50 g amino acids) over 8-12 hours daily.
Not applicable as a single entity; components have independent half-lives. Amino acids have plasma half-lives of minutes to hours depending on individual amino acid and metabolic state. Dextrose has an elimination half-life of 1.5-2.5 hours in normal glucose tolerance. Electrolytes are not described by half-life due to homeostatic regulation.
Amino acids: 0.5-1 hour for free amino acids; terminal half-life of infused nitrogen is approximately 2-4 hours; clinical context: reflects rapid uptake and metabolism.
Amino acids are metabolized in the liver and peripheral tissues via transamination, deamination, and urea cycle. Dextrose is metabolized via glycolysis and the Krebs cycle. Electrolytes are distributed and excreted primarily by the kidneys. Calcium metabolism is regulated by the kidneys, bones, and gastrointestinal tract.
Amino acids are metabolized primarily in the liver via deamination, transamination, and other pathways. The carbon skeletons enter the citric acid cycle or gluconeogenesis, and nitrogen is converted to urea.
CLINIMIX E 2.75/5 is a parenteral nutrition solution; components are eliminated via normal metabolic pathways. Amino acids undergo deamination and oxidation, with nitrogen excreted renally as urea (80-90%). Glucose is metabolized to CO2 and water, excreted via lungs and kidneys. Electrolytes are excreted renally in proportion to intake and homeostatic regulation.
Renal (primarily as amino acids and metabolites); ~90% of infused amino nitrogen is excreted renally within 24-48 hours; <5% biliary/fecal.
Amino acids are minimally protein bound (<10%); dextrose is not protein bound; electrolytes such as calcium and magnesium are partially bound to albumin (calcium ~50% bound, magnesium ~30% bound). Multivalent cations bind to various plasma proteins.
Amino acids: negligible protein binding (<5%); albumin binds some tryptophan and branched-chain amino acids minimally.
Not a single value. Amino acids distribute into total body water (~0.6 L/kg); dextrose distributes mainly into extracellular fluid (~0.2 L/kg) but is rapidly taken up by cells; electrolytes distribute according to their physiological compartments (e.g., sodium extracellular, potassium intracellular).
Amino acids: 0.3-0.5 L/kg (approximates extracellular fluid volume); clinical meaning: distributes primarily in ECF.
Intravenous administration yields 100% bioavailability. Not administered via other routes.
Intravenous: 100% (only route of administration); not absorbed orally as parenteral formulation.
GFR > 50 m L/min: No adjustment needed. GFR 30-50 m L/min: Reduce volume by 50% or use a lower concentration of amino acids and electrolytes, monitor serum potassium, phosphate, and magnesium. GFR < 30 m L/min: Contraindicated or use extreme caution with dose reduction and close monitoring of electrolytes and fluid balance.
GFR <50 m L/min: reduce dose to 0.5-0.8 g/kg/day. GFR <15 m L/min: avoid or use with extreme caution, monitor serum amino acids.
Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce amino acid dose by 50% and monitor for hyperammonemia. Child-Pugh C: Use with caution; avoid if severe hepatic encephalopathy; may require reduction or use of specialized amino acid formulations.
Child-Pugh class B: reduce dose by 50%. Child-Pugh class C: contraindicated due to risk of hepatic encephalopathy.
Weight-based dosing: Initiate at 0.5-1 g/kg/day of amino acids, increasing gradually to a target of 2-3 g/kg/day. Dextrose: start at 5-10 mg/kg/min, increase as tolerated up to 12-15 mg/kg/min. Electrolytes: adjust based on serum levels. Total volume: typically 100-150 m L/kg/day for infants, adjusted for clinical condition.
Neonates: 2-3 g/kg/day IV. Infants/children: 1.5-2.5 g/kg/day IV. Adjust based on metabolic status and growth.
Elderly patients may have reduced renal and hepatic function. Start at lower end of dosing range (e.g., 1 L/day or less) and titrate slowly. Monitor fluid balance, electrolytes, and renal function closely. Avoid rapid infusion to prevent fluid overload.
Initiate at low end of adult dose (1 g/kg/day IV), monitor renal function and adjust accordingly; consider reduced metabolic clearance.
This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions which contain aluminum.
None
Monitoring: serum electrolytes, blood glucose, fluid balance, liver function, renal function, and acid-base status,Risk of hyperglycemia, hyperosmolar state, and metabolic acidosis,Risk of aluminum toxicity, especially in renal impairment and premature infants,Do not administer unless solution is clear and container is undamaged,Use with caution in patients with heart failure, renal failure, or hepatic impairment
Risk of hyperammonemia, especially in patients with hepatic impairment or inborn errors of urea cycle,Electrolyte imbalances may occur; monitor serum electrolytes frequently,Monitor for signs of infection at infusion site,Use caution in patients with renal impairment, as accumulation of amino acids may occur,May cause metabolic acidosis in certain patients
Hypersensitivity to any component,Severe hyperglycemia (e.g., diabetic coma),Drug-induced lactic acidosis,Galactosemia (for dextrose-containing solutions),Severe electrolyte imbalances (unless corrected)
Hypersensitivity to any component,Inborn errors of amino acid metabolism (e.g., maple syrup urine disease, phenylketonuria),Severe hepatic failure with hyperammonemia,Severe renal failure without dialysis support,Patients with uncorrected electrolyte imbalances
No direct food interactions, but parenteral nutrition may affect nutritional status. Enteral intake should be coordinated with the clinical team. Avoid concurrent administration of other IV solutions without compatibility check.
No direct food interactions, but ensure adequate non-protein calorie intake (carbohydrates, fats) to prevent amino acid utilization for energy. Avoid concurrent use with high-protein oral diets without medical supervision. For patients with phenylketonuria (PKU), verify product composition as some contain phenylalanine.
No known teratogenic risk; components (amino acids, dextrose, electrolytes) are physiological and essential for fetal development. No trimester-specific risks identified with standard use.
Aminosyn 10% is an amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this formulation. In the first trimester, the risk of teratogenicity is theoretical; essential amino acids are necessary for fetal development, but excesses or imbalances may be harmful. During the second and third trimesters, supplementation may be beneficial for maternal and fetal nutrition, but potential risks include metabolic acidosis or electrolyte disturbances if not properly monitored.
Considered compatible with breastfeeding; components are normal constituents of human milk. M/P ratio not applicable as mixture of nutrients; no adverse effects reported.
Aminosyn 10% is not excreted into breast milk in significant amounts; its components are endogenous substances. The M/P ratio is not applicable as it is not a drug with active transport. Maternal use during breastfeeding is considered safe if the infusion is necessary for maternal health. No adverse effects on the nursing infant are expected.
No specific dose adjustments required; standard dosing per maternal weight and nutritional needs. Monitor for gestational changes in fluid and electrolyte requirements.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering amino acid clearance. However, no specific dose adjustments are established for Aminosyn 10%. Dosage should be individualized based on nitrogen balance, weight gain, and metabolic parameters. Close monitoring of amino acid levels and metabolic status is recommended to avoid toxicities or deficiencies.
CLINIMIX E 2.75/5 with electrolytes in dextrose 5% and calcium is a parenteral nutrition solution for IV use only. Monitor serum electrolytes, glucose, and renal function closely; do not administer simultaneously with blood products. Check for precipitate formation; use a dedicated line. Contains sulfite-free formulation for patients with sulfite sensitivity.
Use central line administration for concentrations >5% to reduce thrombophlebitis risk. Monitor serum electrolytes, BUN, glucose, and liver function tests frequently. Adjust infusion rate based on metabolic tolerance; start at 100 m L/hr and increase gradually. Contraindicated in severe hepatic disease, uremia, or maple syrup urine disease. Do not use as a sole source of nutrition; provide concurrent calories from carbohydrates and fats.
This medication is given through a vein (IV) and should be administered only by a healthcare professional.,Report any signs of infection at the IV site, such as redness, swelling, or pain.,Inform your healthcare provider of any history of allergies, especially to sulfites.,This solution provides complete nutrition, including amino acids, electrolytes, and dextrose. You may still eat or drink if permitted by your doctor.,Blood tests will be performed regularly to monitor your electrolyte levels, blood sugar, and kidney function.
This solution provides amino acids for protein building when you cannot eat normally.,Report signs of infection at catheter site: redness, swelling, pain, or drainage.,Common side effects include nausea, flushing, and warmth during infusion.,You will need regular blood tests to monitor kidney, liver, and metabolic function.,Inform your doctor if you have diabetes, kidney disease, or a history of gout.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSYN 10%, answered by our medical review team.
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by CLINIMIX E 2.75/5 is a combination of amino acids, electrolytes, and dextrose used for parenteral nutrition. The amino acids provide substrates for protein synthesis, dextrose supplies caloric energy, and electrolytes maintain acid-base and fluid balance. Calcium is included for bone health and neuromuscular function.. AMINOSYN 10% is a Parenteral Nutrition Solution that works by Aminosyn 10% provides a mixture of essential and non-essential amino acids to support protein synthesis and maintain nitrogen balance in patients unable to tolerate adequate oral or enteral nutrition. Each amino acid serves as a substrate for protein synthesis, hormone production, and other metabolic processes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSYN 10% depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous administration. The dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 1 to 2 L per day of CLINIMIX E 2.75/5 with electrolytes in 5% dextrose with calcium, infused at a rate not exceeding 4 mg/kg/min of dextrose (or as tolerated).. The standard adult dose of AMINOSYN 10% is: Intravenous infusion: 1-1.5 g/kg/day (as amino acids), typically 500 m L of 10% solution (50 g amino acids) over 8-12 hours daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSYN 10% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. No known teratogenic risk; components (amino acids, dextrose, electrolytes) are physiological and essential for fetal development. No trimester-specific risks identified with stand. AMINOSYN 10% is classified as Category C. Aminosyn 10% is an amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.